Following a story · 2 updates
FDA refuses approval of Capricor's Duchenne heart therapy
Aug 21, 2026 – Nov 22, 2026
-
FDA faces August 22 deadline on first Duchenne heart-damage therapy
The FDA's PDUFA target action date on Capricor Therapeutics' deramiocel arrives August 22, three weeks after the agency's advisory committee voted 9 to 3 that the evidence did not support approval.
Read this issue → -
FDA refuses approval of Capricor's Duchenne heart therapy
Capricor said the FDA issued a Complete Response Letter on deramiocel on November 20, stating the data are not sufficient to establish substantial evidence of effectiveness, and the company reported about $198.5 million in cash and securities on September 30.
Read this issue →